Personne :
Zarifi Khosroshahi, Mitra

Photo de profil
Adresse électronique
Date de naissance
Projets de recherche
Structures organisationnelles
Fonction
Nom de famille
Zarifi Khosroshahi
Prénom
Mitra
Affiliation
Université Laval. Faculté de pharmacie
ISNI
ORCID
Identifiant Canadiana
ncf11930132
person.page.name

Filtres

20181
Réinitialiser les filtres

Paramètres

Sujet: Antimitotics ×

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • Publication
    Accès libre
    4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells
    (Elsevier, 2018-09-04) Chavez Alvarez, Atziri Corin; Zarifi Khosroshahi, Mitra; Fortin, Sébastien; Côté, Marie-France; Gagné-Boulet, Mathieu
    The role and the importance of the sulfonate moiety in phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) were assessed using its bioisosteric sulfonamide equivalent leading to new cytochrome P450 1A1 (CYP1A1)-activated prodrugs designated as 4-(3-alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides (PAIB-SAs). PAIB-SAs are active in the submicromolar to low micromolar range showing selectivity toward CYP1A1-expressing MCF7 cells as compared to cells devoid of CYP1A1 activity such as MDA-MB-231 and HaCaT cells. The most potent, PAIB-SA 13, bearing a trimethoxyphenyl group on ring B blocks the cell cycle progression in G2/M phase, disrupts the microtubule dynamics and is biotransformed by CYP1A1 into CEU-638, its potent antimicrotuble counterpart. Structure-activity relationships related to PAIB-SOs and PAIB-SAs evidenced that PAIB-SOs and PAIB-SAs are true bioisosteric equivalents fully and selectively activatable by CYP1A-expressing cells into potent antimitotics.